ArticleCurrent microbiology2026
Prokaryotic Expression and Preliminary Application of Lys40, an Endolysin from Broad-Host-Range Salmonella enterica Phage SP_4.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phage endolysins are considered promising novel antimicrobial agents capable of inducing rapid bacterial lysis through efficient degradation of peptidoglycan layers in the cell wall. In this study, the endolysin-encoding gene Lys40 from Salmonella phage SP_4 was subjected to comprehensive bioinformatic analysis. The results indicated that Lys40 contains eight α-helices and two β-strands, belongs to the lyz_endolysin_autolysin domain family (residues 10-147), and lacks both a signal peptide and transmembrane regions. A recombinant expression system was constructed using the pET28b(+) vector and Escherichia coli BL21 (DE3), enabling successful soluble expression of Lys40. Antimicrobial assays demonstrated that, when combined with the permeabilizer EDTA, Lys40 exhibited significant lytic activity not only against Salmonella but also toward E. coli. The observed synergistic antibacterial effect of Lys40 combined with EDTA in this study provides experimental data support for the development of novel antimicrobial agents.
Indexed as
Identifiers
42008022What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.